Minoxidil 20% | Bimatoprost 0.03% | Finasteride 0.1% | Tretinoin 0.05%

Topical scalp application: Apply 1 mL (or as prescribed) of the solution or lotion to clean, dry scalp in the area of hair loss once or twice daily as directed. Part the hair to expose the scalp and apply directly using the dropper or pump. Gently massage into the scalp. Wash hands thoroughly after application. Do not apply to broken skin or mucous membranes. Allow the preparation to dry before lying down or using pillowcases, as tretinoin and minoxidil may stain fabric. Avoid contact with eyes and face — tretinoin 0.05% can cause significant facial irritation. Do not wash the scalp for at least 4 hours after application.

Application frequency and volume are prescriber-determined. Given the high minoxidil concentration (20%) and tretinoin (0.05%):

• Typically applied once daily to limit tretinoin-related irritation while maximizing follicular exposure.
• Clinical response (reduced shedding, early regrowth) is generally evident at 3–6 months; cosmetically visible improvement at 6–12 months.
• An initial telogen effluvium (temporary increased shedding at 4–8 weeks) is expected and indicates follicular cycle reset — continuation of therapy is appropriate.
• Final dosing schedule, volume, and frequency are prescriber-determined.

• Minoxidil 20%: A potassium channel opener (specifically KATP channels) that hyperpolarizes the follicular dermal papilla cell membrane, increasing cellular uptake of growth factors. Its sulfate metabolite (minoxidil sulfate) is the active form, requiring follicular sulfotransferase (SULT1A1). It also stimulates vascular endothelial growth factor (VEGF) and activates Wnt/β-catenin signaling, lengthening the anagen phase.
• Bimatoprost 0.03%: An analog of prostaglandin F2α that binds FP and prostamide receptors on follicular dermal papilla cells. Stimulates transition of resting (telogen) follicles into the active growth (anagen) phase, increases follicular proliferation, and extends anagen duration. Originally identified for eyelash growth (FDA-approved as Latisse for hypotrichosis).
• Finasteride 0.1%: Competitively inhibits type II 5α-reductase, the enzyme predominantly responsible for intrafollicular conversion of testosterone to the more potent androgen DHT. DHT binds androgen receptors in sensitive dermal papilla cells, causing progressive follicular miniaturization in AGA. Topical delivery at 0.1% achieves local scalp DHT reduction with substantially less systemic DHT suppression than oral finasteride 1 mg/day.
• Tretinoin 0.05%: A retinoic acid that binds nuclear retinoic acid receptors (RARs), regulating gene expression related to keratinocyte differentiation. It disrupts the stratum corneum lipid bilayer and increases transcellular permeability, enhancing minoxidil penetration to the follicular papilla by approximately 3-fold. Independently, ATRA activates Wnt/β-catenin and promotes anagen induction.

Indication: Androgenetic alopecia (male-pattern or female-pattern hair loss) in patients who have failed or are unsuitable for monotherapy, or in whom a multi-mechanism approach is desired. The four-component formulation targets vasodilation/anagen prolongation (minoxidil), prostaglandin-mediated follicular cycling (bimatoprost), DHT inhibition (finasteride), and percutaneous drug delivery enhancement (tretinoin).

Prescriber monitoring:

• Photograph baseline scalp area with standardized technique; repeat at 6 and 12 months
• Assess scalp tolerance to tretinoin — irritation, scaling, or erythema may require reducing application frequency
• Serum DHT and testosterone if systemic hormonal effects are of concern (particularly in women of reproductive age or men with sexual function concerns)
• In women of childbearing potential: finasteride is a teratogen (Category X for female fetus) — confirm non-pregnancy status and contraception before prescribing

Contraindications:

• Pregnancy or planned pregnancy (finasteride — Category X for female fetuses; tretinoin — teratogen in systemic form, topical risk unquantified)
• Hypersensitivity to any component
• Do not apply to broken skin, face, or mucous membranes

Warnings & Precautions:

• Finasteride: even topical absorption may reduce serum DHT; sexual side effects (reduced libido, ejaculatory dysfunction) have been reported with topical finasteride, though less frequently than with oral formulations — counsel appropriately
• Tretinoin: photosensitization — advise sun protection; may cause significant scalp or adjacent facial irritation
• Minoxidil 20%: high concentration — systemic absorption and cardiovascular effects (tachycardia, fluid retention) are possible if applied to large surface areas or broken skin
• Bimatoprost: may cause periorbital hyperpigmentation if inadvertent eye contact occurs

Drug Interactions:

• Topical retinoids and concurrent topical irritants: additive scalp irritation
• Systemic antihypertensives: theoretical additive hypotensive effect if minoxidil is significantly absorbed

Common Side Effects: Scalp itching, irritation, or scaling (tretinoin); initial increased shedding (telogen effluvium, 4–8 weeks); facial hypertrichosis if preparation contacts forehead skin; skin discoloration near application site (bimatoprost).

Store at room temperature (15–25°C), away from light and heat. Do not freeze. The retinoid component (tretinoin) is light-sensitive and will degrade in UV exposure; store in an opaque container. Keep tightly capped. Observe the beyond-use date. Shake or stir gently if separation occurs (confirm instructions with the dispensing pharmacy).

Why does this formulation have four ingredients?

Androgenetic alopecia has multiple simultaneous pathogenic mechanisms — androgen-driven miniaturization, follicular cycling abnormalities, reduced scalp blood flow, and drug penetration barriers. Each ingredient in this preparation addresses a distinct pathway, and clinical evidence suggests that combination therapies outperform monotherapies in hair density outcomes.

Will I experience a period of increased hair loss after starting?

Yes. An initial telogen effluvium — shedding of resting hairs displaced by newly activated anagen follicles — commonly occurs within 4–8 weeks of starting minoxidil-containing therapy. This is a normal and expected sign of follicular activation; continue treatment and reassess at 3 months.

Is the finasteride in this topical formulation safer than the oral pill?

Topical finasteride achieves local scalp DHT reduction with lower systemic DHT suppression than 1 mg oral finasteride, reducing but not eliminating the risk of systemic androgen-related side effects. Sexual adverse effects have been reported with topical finasteride, though at lower rates. Female patients of childbearing potential should use effective contraception.

Can women use this formulation?

Women with female-pattern hair loss can use minoxidil, bimatoprost, and tretinoin. Finasteride in any form is contraindicated in pregnancy (teratogen — Category X) and requires careful risk-benefit assessment in women of reproductive potential. Prescribers will individualize the formulation accordingly.

Is this FDA-approved?

Individual components are FDA-approved in different forms and for different indications; this specific four-component compounded topical is not FDA-approved. It is prepared by Genesis Compounding as a prescriber-directed, patient-specific 503A compounded preparation.